Skip to main content

Navigation group

Type at least 3 characters
1,085 articles

Articles

Brief Research Report

Published on 02 Feb 2022

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

in Gastrointestinal and Hepatic Pharmacology

  • Alana Aragón-Herrera
  • Manuel Otero-Santiago
  • Laura Anido-Varela
  • Sandra Moraña-Fernández
  • Manuel Campos-Toimil
  • Tomás García-Caballero
  • Luis Barral
  • Estefanía Tarazón
  • Esther Roselló-Lletí
  • Manuel Portolés
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
Frontiers in Pharmacology
doi 10.3389/fphar.2022.827033
  • 4,470 views
  • 5 citations